All Posts Tagged With: "NVS"
(AMD) Roche Holdings Gets Positive Data on Lucentis
Roche Holdings Ltd. (RHHBY) recently reported positive data from two late-stage studies (RISE and RIDE) on its eye drug, Lucentis. The studies were conducted to evaluate the safety and efficacy of the drug...
(NVS) Novartis AG Afinitor Backed in EU
Novartis AG (NVS) received a boost recently when the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommended approval of its drug Afinitor for the treatment...
(REGN) Bayer Seeks Eylea Approval in Japan
Germany’s Bayer (BAYRY) recently submitted an application to the Japanese Ministry of Health, Labor and Welfare (MHLW) seeking approval to market its eye treatment VEGF (vascular endothelial growth factor)...
(WPI) Watson Pharmaceuticals Files More Abbreviated New Drug Applications
Watson Pharmaceuticals Inc. (WPI) recently announced that it has filed Abbreviated New Drug Applications (ANDA) with the US Food and Drug Administration (FDA) to market its generic version of GlaxoSmithKline...
(RDY) Dr. Reddy’s Laboratories Launches Generic Levaquin
Dr. Reddy’s Laboratories (RDY) recently announced the launch of its generic version of Johnson & Johnson’s (JNJ) antibiotic drug,...
(CTIC) Cell Therapeutics Analyst Mintains Neutral on Shares
We are maintaining a Neutral recommendation on Cell Therapeutics Inc. (CTIC) with a target price of $2.25.
Cell Therapeutics Inc. based in Seattle, Washington, is focused on developing drugs for cancer....
(ALNY) Alnylam Pharmaceuticals Analyst Maintains Neutral on Shares
We have maintained a Neutral rating on Alnylam Pharmaceuticals Inc. (ALNY) with a target price of $9.50 per share.
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company developing novel therapeutics...
(NVS) Novartis Gets Setback From FDA Panel
Novartis (NVS) received a setback recently when an advisory panel to the US Food and Drug Administration (FDA) recommended against approving its pipeline candidate ACZ885 for the proposed indication.
Novartis...
(BIIB) Biogen Idec and Partner Elan Announce EU Label Update for Tysabri
Recently, Biogen Idec, Inc. (BIIB) and partner Elan Corporation (ELN) announced that the European Commission (EC) has approved an update...
(MYL) Trial Date for Teva Pharmaceuticals / Mylan Dispute
Mylan Inc. (MYL) received some good news recently when a US District court denied Teva Pharmaceuticals Industries’ (TEVA) motion for a...
(REGN) Regeneron Pharmaceuticals Wins Unanious FDA Panel Approval
Recently, the Dermatologic and Ophthalmic Advisory Committee of the US Food and Drug Administration (FDA) issued a positive opinion and unanimously recommended the US approval of Regeneron Pharmaceuticals Inc.’s (
21Jun2011 | vitalstocks | 0 comments | Continued(RDY) Dr. Reddy’s Laboratories Announces FDA Warning Letter
Dr. Reddy’s Laboratories (RDY) recently announced that the US Food and Drug Administration (FDA) issued a four item warning letter regarding the company’s chemical manufacturing facility at Cuernavaca,...
(INCY) Incyte Corporation Analyst Maintains Neutral on Shares
We are maintaining our Neutral recommendation on Incyte Corporation (INCY) with a target price of $18.00.
Incyte is a Wilmington, Delaware-based drug discovery and development company with a focus...
(AKRX) Company News for June 07, 2011 – Corporate Summary
• Share prices of home nursing provider Amedisys, Inc.(NASDAQ:AMED) fell 7.41% after CRT Capital reduced its earnings estimates for fiscal 2011
• According to Canaccord Genuity, data from a trial of...
(MYL) Mylan Launches New Generic Pharmaceuticals
Mylan Inc.’s (MYL) generic portfolio continued to be boosted with the launch of the generic version of Xanodyne Pharmaceutical’s pain reliever Roxicodone. The generic has been launched under a development...
(MYL) Mylan Launches Generic Drugs
MylanInc. (MYL) recently launched its generic version of Ista Pharmaceuticals Inc’s (ISTA) Xibrom ophthalmic solution,...
(MYL) Mylan Meets Analyst Estimates – Sales Upbeat
Mylan Inc.’s (MYL) first quarter 2011 earnings (excluding special items) of 44 cents per share were in line with the Zacks Consensus Estimate. A higher quarterly tax rate, increased share count and pricing...
(NVS) Novartis Posts Solid First Quarter Sales
Novartis (NVS) reported earnings per share of $1.41 for the first quarter of 2011, below the year-earlier earnings of $1.45 per share but well ahead of the Zacks Consensus Estimate of $1.31. The drop from...
(MRK) Five Large Cap Pharmaceuticals to Consider
The Large Cap Pharma sector is the fastest rising sector on Barchart when screening for the 1 month price change. The general investing public is very interested in this sector as evidenced by the 25,409 opinions expressed on Motley Fool on the 5 stocks I selected. Before...
(BIIB) Biogen Idec Earnings Above Estimates on Multiple Sclerosis Drugs
Biogen Idec (BIIB) reported first-quarter earnings per share of $1.42, 3 cents above the Zacks Consensus Estimate of $1.39 and well above the year-earlier figure of $1.04. Excluding the impact of stock-based...
(BIIB) Biogen Idec Earnings Report Beats The Street
Biogen Idec (BIIB) reported first-quarter earnings per share of $1.42, 3 cents above the Zacks Consensus Estimate of $1.39 and well above the year-earlier figure of $1.04. Excluding the impact of stock-based...
(BIIB) Biogen’s Oral Multiple Sclerosis Drug Impresses
Biogen (BIIB) received a boost recently with the company presenting promising top-line data on its oral multiple sclerosis candidate, BG-12. The company presented positive results on the use of BG-12 as a...
(NVS) Novartis’ Tasigna Trial for Gastrointestinal Stromal Tumor Halted
Novartis (NVS) faced a pipeline setback recently as it announced discontinuation of a late-stage study (ENESTg1) of its drug Tasigna on the recommendation of an independent data monitoring committee. The study...
(ALNY) Alnylam Pharmaceuticals Signs IP Deal with NYU
Alnylam Pharmaceuticals Inc. (ALNY) recently announced that it has received an exclusive license from the New York University (NYU) for intellectual property covering therapeutic uses of miR-33a and miR-33b...
(SHPGY) Shire and Watson Pharmaceuticals in Patent Legal Battle
The legal tussle between Shire (SHPGY) and Watson Pharmaceuticals Inc. (WPI) intensified with the Ireland based Shire filing a case of...
(MYL) Mylan Analyst Maintains Neutral Rating on Shares
We have maintained our Neutral recommendation on Mylan Inc. (MYL) with a target price of $23.00 after appraising fourth quarter and fiscal year 2010 financial results.
Mylan’s fourth quarter 2010...
(WPI) Watson Pharmaceuticals Analyst Maintains Neutral Rating on Shares
We recently reaffirmed our Neutral stance on Watson Pharmaceuticals Inc. (WPI) following the release of fourth quarter and fiscal year 2010 financial results. Quarterly earnings of 93 cents per share were...
(PDLI) PDL BioPharma Ramps Up Earnings – Settles Disputes
PDL BioPharma Inc. (PDLI) posted fourth quarter earnings of 20 cents per share, above the year-ago figure of 17 cents. Higher revenues boosted earnings in the quarter. Earnings per share were, however, a...
(AMZN) Company News for March 01, 2011 – Corporate Summary
• Board of Directors of both Ventas, Inc. (NYSE:VTR) and Nationwide Health Properties, Inc. (NYSE:NHP) have approved a definitive merger agreement between the two companies
• Titanium...
(BIIB) Biogen Quarterly Earnings Report Beats by a Wide Margin
Biogen Idec (BIIB) reported fourth-quarter earnings per share of $1.41, well above the Zacks Consensus Estimate of $1.23 and the year-earlier figure of $1.18. Excluding the impact of stock-based compensation...